Torsemide (Demadex)

A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.

Also Known As:

Networked: 255 relevant articles (44 outcomes, 70 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Mentz, Robert J: 9 articles (10/2022 - 03/2015)
2.	Velazquez, Eric J: 7 articles (10/2022 - 03/2015)
3.	Díez, Javier: 7 articles (01/2018 - 08/2002)
4.	Anstrom, Kevin J: 6 articles (10/2022 - 03/2015)
5.	Greene, Stephen J: 6 articles (10/2022 - 01/2018)
6.	Watanabe, Kenichi: 6 articles (10/2017 - 02/2008)
7.	Eisenstein, Eric L: 5 articles (10/2022 - 03/2015)
8.	González, Arantxa: 5 articles (01/2018 - 06/2004)
9.	López, Begoña: 5 articles (01/2018 - 06/2004)
10.	Harima, Meilei: 4 articles (10/2017 - 07/2009)

Related Diseases

1.	Heart Failure 09/01/2020 - "Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study." 01/01/2017 - "The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial." 07/01/2010 - "Clinical trials have indicated that torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failure-related hospitalization. " 08/01/2009 - "This trial will test whether torasemide-PR possesses antifibrotic properties, which may provide an additional benefit beyond diuresis in patients with chronic heart failure." 08/01/2002 - "Torasemide in chronic heart failure: results of the TORIC study."
2.	Fibrosis (Cirrhosis) 08/28/2007 - "These findings suggest the hypothesis that the ability of torasemide to reduce myocardial fibrosis in chronic HF patients is related to a decreased PCP activation. " 01/01/1998 - "A greater than normal fraction of torasemide was recovered in the urine of patients with cirrhosis. " 07/01/1993 - "Pharmacokinetic changes of torsemide in cirrhosis therefore compensate for the pharmacodynamic abnormality." 07/01/1993 - "Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis." 08/01/2009 - "The aim of the TORAFIC study is to test the efficacy of torasemide prolonged-release formulation (PR) in reducing myocardial fibrosis in chronic heart failure in a large, randomized clinical trial. "
3.	Hypertension (High Blood Pressure) 01/01/2021 - "Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)." 09/01/2022 - "Ten days prior to admission, she was commenced on torasemide at a dose of 50 mg per day prescribed by a general practitioner due to high blood pressure. " 01/01/2021 - "In addition, for the first time in hypertensive patients, European Society of Hypertension (ESH) guidelines recommend the use of torasemide. " 11/01/2018 - "The rate of persistent postpartum hypertension was 44% in the torsemide and 58% in the placebo group (relative risk 0.76, 95% CI 0.5-1.1). " 01/01/2008 - "Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release."
4.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/1998 - "In chronic renal failure the renal clearance of torasemide decreased in proportion to the decrease of the patients' glomerular filtration rate, whereas the total plasma clearance (3 times that of the renal clearance) appeared to be independent of renal function. " 01/01/1994 - "The results of this study suggest that despite the increased half-life of torasemide metabolites M1, M3 and M5 in end-stage renal failure patients, no accumulation of the parent drug torasemide and its metabolites during chronic dosing is demonstrable." 01/01/1991 - "The results of a study with torasemide given intravenously in healthy subjects and in patients with stable chronic renal failure of various degrees are reported and discussed. " 07/01/1997 - "High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure." 01/01/1994 - "Pharmacokinetics of torasemide and its metabolites in end-stage renal disease."
5.	Body Weight (Weight, Body) 09/01/1994 - "At the end of the study, patients treated with torsemide 10 and 20 mg demonstrated a significant reduction in body weight compared with those receiving placebo (-1.62 and -1.30 kg, respectively), and those treated with torsemide 5 mg did not (-0.60 kg). " 11/01/1996 - "Patients who received the placebo showed a significantly greater (p < 0.001) mean increase in body weight (3.55 lb) than did patients who remained on torsemide (0.46 lb). " 02/01/2010 - "Torasemide elimination was significantly reduced in women compared with men (eg, body-weight-normalized area under the concentration-time curve: 42.1 +/- 20.4 vs 30.9 +/- 10.3 kg.h/L; P < .001). " 05/01/1999 - "Except for body weight, patient demographic characteristics did not differ between groups at baseline; patients in the torsemide group were significantly heavier (P = 0.004). " 01/01/1994 - "After the end of the infusion 100 mg torasemide/kg body weight or a corresponding volume of isotonic saline were injected followed by continuous continued recording of ICP and systemic arterial pressure for at least 3 hours. "

Related Drugs and Biologics

1.	Furosemide (Lasix)
2.	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)
3.	Diuretics
4.	Antihypertensive Agents (Antihypertensives)
5.	Sodium
6.	pyridine
7.	Urea (Carbamide)
8.	Electrolytes
9.	Brain Natriuretic Peptide (Natrecor)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Aftercare (After-Treatment)
4.	Intravenous Administration
5.	Patient Readmission